MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Disorders

Background:

• Cholesterol-lowering drugs like statins, bile acid sequestrants, and cholesterol absorption inhibitors are crucial for cardiovascular prevention.
• Current guidelines recommend defined lipid targets for individuals at high risk of atherosclerotic coronary heart disease.
• Combination therapy is often necessary to achieve lipid targets, but some patients remain unresponsive or intolerant to conventional treatments.

Purpose of the Study:

• To review novel therapeutic approaches for dyslipidaemias focusing on microsomal triglyceride transfer protein (MTP) inhibition.
• To identify patient populations who may benefit from MTP inhibitors.
• To discuss the potential role and safety considerations of MTP inhibitors in managing hyperlipidaemias.

Main Methods:

• Review of existing literature on hyperlipidaemia treatments.
• Focus on the mechanism of action of MTP inhibitors.
• Analysis of patient profiles suitable for MTP inhibitor therapy.

Main Results:

• Microsomal triglyceride transfer protein (MTP) inhibitors represent a promising new class of drugs for hyperlipidaemias.
• These agents are particularly relevant for patients with hepatic overproduction of apoB, including those with metabolic syndrome, Type 2 diabetes mellitus, familial combined hyperlipidaemia, and familial hypercholesterolaemia (homozygous and heterozygous).
• MTP inhibitors can be used alone or in combination therapies.

Conclusions:

• MTP inhibitors offer an alternative treatment strategy for dyslipidaemias, especially for difficult-to-treat patient groups.
• Careful consideration of safety issues, such as the potential for fatty liver disease, is essential for the clinical application of MTP inhibitors.
• Further research is needed to fully establish the role and optimize the use of MTP inhibitors in cardiovascular disease prevention.